Abstract
In common with other E2F1 responsive genes such as p14ARF and B-myb, the promoter of p73 is shown to be positively regulated in cell lines and primary human keratinocytes by E7 proteins from oncogenic human papillomavirus (HPV) types 16, 18, 31 and 33, but not HPV 6. Mutational analysis revealed that transactivation of the p73 promoter by HPV 16E7 requires association with pRb. Expression of p73 in normal cervical epithelium is confined to the basal and supra-basal layers. In contrast, expression in neoplastic lesions is detected throughout the epithelium and increases with grade of neoplasia, being maximal in squamous cell cancers (SCC). Deregulation of expression of the N-terminal splice variant p73Δ2 was observed in a significant proportion of cancers, but not in normal epithelium. The frequent over-expression of p73Δ2, which has recognized transdominant properties, in malignant and pre-malignant lesions suggests a role in the oncogenic process in cervical epithelium.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bates S, Phillips AC, Clarke PA, Stott F, Peters G, Ludwig RL, Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124–125
Chi S-G, Chang S-G, Lee S-J, Lee C-H, Kim JI, Park J-H (1999) Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res 59: 2791–2793
Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′CpG methylation. Cancer Res 59: 3352–3356
De Laurenzi V, Rossi A, Terrinoni A, Barcoroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P, Melino G (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 273: 342–346
De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino GJ (1998) Two new splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188: 1763–1768
Ding Y, Inoue T, Kamiyama J, Tamura Y, Ohtani-Fujita N, Igata E, Sakai T (1999) Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. DNA Res 6: 347–351
Edmonds C, Vousden KH (1989) A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63: 2650–2656
Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK (2001) Transactivation-deficient p73α (p73Delta exon 2) inhibits apoptosis and competes with p53. Oncogene 20: 514–522
Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E (1998) The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 58: 3926–3931
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8: 3905–3910
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin Jr WG (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645–648
Jost CA, Marin MC, Kaelin Jr WG (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389: 191–194
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, DuMont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809–819
Lam E, Lam EW, Morris JD, Davies R, Crook T, Watson RJ, Vousden KH (1994) HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J 13: 871–878
Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF (2000) A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642–645
Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley P (1989) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099–4105
Ng S-W, Yiu GK, Liu Y, Huang L-W, Palnati M, Jun SH, Berkowitz RS, Mok SC (2000) Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19: 1885–1890
Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L (1989) Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 7: 1815–1820
Troncone G, Martinez JC, Palombini L, De Rosa G, Mugica C, Rodriguez JA, Zeppa P, Di Vizio D, Lucariello A, Piris MA (1998) Immunohistochemical expression of mdm2 and p21Waf1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection. J Clin Pathol 51: 754–760
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 1–3
Zaika AI, Kovalev S, Marchenko ND, Moll UM (1999) Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 59: 3257–3263
Zaika A, Irwin M, Sansome C, Moll UM (2001) Oncogenes induce and activate endogenous p73 protein. J Biol Chem 276: 11310–11316
Acknowledgements
We are very grateful to Professor Ute Moll for providing pE1A, and to Dr William Kaelin for the anti-p73 antibody.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brooks, L., Sullivan, A., O'Nions, J. et al. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer 86, 263–268 (2002). https://doi.org/10.1038/sj.bjc.6600033
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600033